King Wealth Management Group’s Aldeyra Therapeutics ALDX Stock Holding History

King Wealth Management Group’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20K	Buy	11,900 +1,100	+10%	+$4.82K	﹤0.01%	158
2025 Q4	$56K	Sell	10,800 -300	-3%	-$1.54K	0.01%	163
2025 Q3	$58K	Sell	11,100 -1,000	-8%	-$5.21K	0.01%	159
2025 Q2	$46K	Buy	+12,100	New	+$31.3K	0.01%	158
2025 Q1	–	Sell	-13,500	Closed	-$67K	–	158
2024 Q4	$67K	Sell	13,500 -200	-1%	-$1.03K	0.01%	153
2024 Q3	$74K	Buy	13,700 +2,700	+25%	+$12.9K	0.01%	150
2024 Q2	$36K	Buy	11,000 +1,000	+10%	+$3.92K	0.01%	143
2024 Q1	$33K	Buy	+10,000	New	+$32.9K	0.01%	145

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

King Wealth Management Group's ALDX Position: Q1 2026 in Review

King Wealth Management Group increased its Aldeyra Therapeutics (ALDX) stake by 10% in Q1 2026, buying an estimated $4.82K and bringing the position to 11,900 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #158.

King Wealth Management Group first reported a position in ALDX in Q1 2024 and has held it in 8 quarters since. The position peaked at $74K in Q3 2024. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

King Wealth Management Group held 11,900 shares of Aldeyra Therapeutics worth $20K as of Q1 2026.
King Wealth Management Group bought 1,100 Aldeyra Therapeutics shares in Q1 2026, an estimated $4.82K.
Aldeyra Therapeutics made up ﹤0.01% of King Wealth Management Group's portfolio in Q1 2026, its #158 holding.
King Wealth Management Group first reported a position in Aldeyra Therapeutics in Q1 2024 and has held it in 8 quarters since.
King Wealth Management Group's Aldeyra Therapeutics position peaked at $74K in Q3 2024.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on King Wealth Management Group's 13F filing for Q1 2026, filed 4 May 2026.